🔥Telegram İfşa

Asciminib was active in heavily pretreated patients with CML who had resistance to or unacceptable side effects from TKIs, including patients in whom ponatinib had failed and those with a T315I mutation. nej.md/2E6Ptxk

Editorial: Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation ow.ly/bgQ050zA5oX

So proud of Jennifer Miller and her research presentation at ASH! :)

Wonderful presentation on the Updates from ASH 2020 from Cindy Herrera, PharmD, BCOP at TCT this year! If you didn’t catch it, make sure to go back and watch! I was lucky enough to collaborate with her and present the second half! #TCTM21 #oncopharm Lurie Cancer Center Northwestern Medicine

Had a great time seeing past & current Northwestern Medicine colleagues Barbara Pro @reemkarmali Daniel Wojenski at Ultmann Chicago Lymphoma Conference Lurie Cancer Center

Northwestern Pride! 💜🏳️‍🌈 Daniel Wojenski Brendan @jerbunnyman